보고서 요약(국문)

시장 개요
대상포진 백신 시장은 2023년부터 2030년까지 예측 기간 동안 연평균 10.00%의 성장률을 기록할 것으로 예상됩니다.
이 백신은 미국, 캐나다, 독일, 영국 등 많은 선진국에서 권장되고 있습니다. 호주에서는 70세 이상 성인을 대상으로 국가 예방접종 프로그램(NIP)을 통해 대상포진 백신을 무료로 제공하고 있습니다. 이탈리아, 영국, 미국 등 여러 국가에서도 대상포진 발병률 감소를 위해 국가 예방접종 프로그램에 대상포진 백신 접종을 포함시켰습니다. 호주는 70세 이상 성인을 대상으로 대상포진 백신 접종을 위한 재정 지원 시설을 제공하고 있습니다. 이러한 요인들로 인해 대상포진 백신 시장은 향후 몇 년 동안 상당한 성장세를 보일 것으로 전망됩니다.
대상포진 백신 접종의 비용 효율성은 전 세계 대상포진 백신 시장 성장의 주요 동인입니다. 미국 질병통제예방센터(CDC)에서 권장하는 대상포진 백신인 싱그릭스(Shingrix)는 6개월 이내에 2회 접종하는 재조합 대상포진 백신입니다. 대상포진 치료는 비용이 매우 많이 들고 증상 완화에만 도움이 됩니다. 의료 전문가들은 백신 접종의 효과 때문에 널리 권장하고 있습니다. 대상포진 백신의 치료 대비 비용 효율성은 향후 예측 기간 동안 전 세계 대상포진 백신 시장 성장의 주요 동력이 될 것입니다.
대상포진이란 무엇인가요?
대상포진은 뇌에서 시작되는 뇌신경에 영향을 미치는 바이러스 감염입니다. 수두를 일으키는 바이러스인 수두대상포진 바이러스(varicella-zoster virus)에 의해 발생합니다. 대상포진 백신은 대상포진 발병률을 줄여주는 백신입니다. CDC는 50세 이상 성인에게 대상포진 및 그로 인한 합병증 예방을 위해 싱그릭스(재조합 대상포진 백신) 2회 접종을 권장합니다. 대상포진은 체내 수두 바이러스가 재활성화되어 발생하는 바이러스 감염입니다. 이 질병은 몸통이나 다른 신체 부위에 물집이 띠 모양으로 나타날 수 있으며, 발진이 사라진 후에도 통증이 지속됩니다. 치료는 질병의 지속 기간을 단축하고 증상을 완화하는 데 그치기 때문에 정부에서는 백신 접종을 널리 권장하고 있습니다.
지역별 주요 분석:
북미는 대상포진 발병률이 높아 전 세계 대상포진 백신 시장의 핵심 지역입니다. 또한 이 지역에는 새로운 백신 및 대상포진 치료법 연구를 진행하는 주요 제약 및 생명공학 기업들이 있습니다. 예를 들어, 2021년 글락소스미스클라인(GlaxoSmithKline plc)은 미국과 캐나다에서 Shingrix 백신의 규제 승인을 받았다고 발표했습니다. 북미 대상포진 백신 시장은 향후 몇 년 동안 상당한 성장을 보일 것으로 예상됩니다.
유럽에서는 대상포진 발병률이 상대적으로 낮습니다. 하지만 독일, 영국, 이탈리아 등 유럽 주요 국가에서는 예방 접종이 시행되고 있습니다. 예방 접종은 유럽 대상포진 백신 시장의 성장을 견인할 것으로 예상됩니다.
아시아 태평양 지역에서 대상포진 발병률이 증가함에 따라 대상포진 백신 시장에 새로운 기회가 열리고 있습니다. 중국에서는 50세 이상 인구에서 매년 150만 건 이상의 대상포진 신규 환자가 발생하고 있는데, 이는 노화로 인한 세포 면역력 감소 때문입니다. 일본 또한 매년 60만 건 이상의 대상포진 환자가 발생하고 있으며, 이는 주로 고령화 인구 증가에 기인합니다.
시장 성장 동향 및 제약 요인:
대상포진 백신과 관련된 부작용은 전 세계 대상포진 백신 시장의 성장을 저해할 것으로 예상됩니다.
예측 기간 동안 대상포진 백신과 관련된 부작용은 전 세계 대상포진 백신 시장의 성장을 저해할 것으로 예상됩니다. 대부분의 사람들은 대상포진 백신 접종 후 팔에 경미하거나 중간 정도의 통증을 느끼며, 주사 부위가 붉어지고 부어오를 수 있습니다. 다른 부작용으로는 근육통, 두통, 오한, 발열, 복통, 메스꺼움 등이 있습니다. 드물게 아나필락시스와 같은 심각한 알레르기 반응이 나타날 수 있는데, 이는 생명을 위협할 수 있지만 치료가 가능합니다.
재조합 백신으로의 전환이 증가함에 따라 세계 시장에 새로운 기회가 창출될 것으로 예상됩니다.
재조합 대상포진 백신은 주요 면역 문제가 없는 50세 이상 성인에게 권장됩니다. 이 백신은 2회 접종으로 투여됩니다. 재조합 대상포진 백신은 2회 접종이 필요하지만 90% 이상의 효능을 보이며 더 긴 기간 동안 예방 효과를 제공합니다. 따라서 재조합 백신으로의 전환이 증가함에 따라 향후 시장에 새로운 기회가 창출될 것으로 기대됩니다.

대상포진에 대한 낮은 인식은 세계 시장에 어려움을 초래할 것으로 예상됩니다.
PUBMED가 실시한 설문조사에 따르면 인도, 터키와 같은 주요 개발도상국에서 대상포진에 대해 알고 있는 사람은 20% 미만이었습니다. 이 설문조사는 대상포진의 원인과 증상에 대한 지식이 전반적으로 부족하다는 것을 보여주었습니다. 대상포진에 대한 낮은 인식은 세계 대상포진 백신 시장의 성장에 어려움을 줄 것으로 예상됩니다.
코로나19 영향 분석
코로나19 팬데믹은 세계 시장에 긍정적 및 부정적인 영향을 모두 미쳤습니다. 코로나19 감염은 면역력이 저하된 사람들에게서 대상포진을 재활성화시켰습니다. 또한, 백신 제조업체들이 코로나19 백신 생산을 우선시하면서 대상포진 백신의 생산 및 판매가 감소했습니다. 팬데믹으로 인한 어려움에도 불구하고, 세계 대상포진 백신 시장은 예측 기간 동안 성장세를 회복할 것으로 예상됩니다.

최근 산업 동향:
1. 2021년 7월, 글락소스미스클라인(GlaxoSmithKline plc)은 미국 식품의약국(FDA)으로부터 재조합 대상포진 백신인 신그릭스(Shingrix)의 승인을 받았다고 발표했습니다.
2. 2022년 7월, 중국 생명공학 기업인 맥스박스 바이오테크놀로지(Maxvax Biotechnology)와 베이징 루주 바이오테크놀로지(Beijing Luzhu Biotechnology)는 재조합 대상포진 백신 후보 물질에 대한 여러 임상 시험을 위해 7,400만 달러를 투자 유치했습니다.
3. 2021년 10월, 미국 질병통제예방센터(CDC) 패널은 면역결핍 또는 면역억제 상태의 성인을 위한 대상포진 백신으로 신그릭스를 권장하기로 결정했습니다.
시장 세분화:
본 보고서는 제품, 백신 유형, 유통 채널 및 지역별 시장 세분화를 다룹니다. 제품별로는 신그릭스, 조스타박스(Zostavax), 스카이조스터(SKYZoster)로 구분됩니다. 백신 유형별로는 재조합 백신과 생백신으로 구분됩니다. 전 세계 대상포진 백신 시장은 유통 채널별로 병원 약국, 소매 약국 및 기타로 구분됩니다.
1. 재조합 백신: 재조합 백신은 사람과 동물의 치명적인 질병 예방을 위해 재조합 DNA 기술 또는 유전자 공학을 사용하여 생산됩니다. 재조합 백신은 특정 질병에 대한 능동적 획득 면역을 제공하는 생물학적 제제입니다.
2. 생백신: 생백신은 질병을 유발하는 병원체가 활성 상태로 남아 있는 백신입니다. 생백신은 다른 형태의 백신에 비해 강력한 항체 및 세포 매개 면역 반응 생성, 장기적인 면역, 비교적 빠른 작용 발현 등의 장점을 가지고 있습니다.
경쟁 분석:
전 세계 대상포진 백신 시장은 많은 주요 글로벌 및 지역 기업들이 참여하는 집중화된 시장입니다. 주요 시장 참여 기업들은 인수합병, 제품 승인, 계약 체결 등 다양한 전략을 통해 제품 범위를 확대하고 제품 포트폴리오를 강화하여 대상포진 백신 산업에 진출하거나 사업 영역을 확장하고 경쟁력을 강화하고 있습니다.
주요 기업:
글로벌 대상포진 백신 산업 성장에 기여하는 주요 기업으로는 GlaxoSmithKline plc., Merck & Co. Inc., SK Bioscience, GC Pharma, Vaccitech, Geneone Life Science, Shulov Innovative Science, EYEGENE lnc. 등이 있습니다.
GlaxoSmithKline
개요:
GlaxoSmithKline PLC는 글로벌 헬스케어 기업입니다. 이 회사는 제약 및 백신 두 사업 부문으로 운영됩니다. GlaxoSmithKline은 호흡기 질환, 인간 면역결핍 바이러스(HIV)/감염성 질환, 백신, 면역 염증, 종양학, 희귀 질환 등 6개 분야에 걸쳐 연구에 집중하고 있습니다.

제품 포트폴리오:
싱그릭스(SHINGRIX): 싱그릭스는 50세 이상 성인의 대상포진(헤르페스 조스터) 예방을 위해 FDA 승인을 받은 백신입니다. 싱그릭스는 수두 예방에는 사용되지 않습니다.
구매 후 추가 혜택:
1) 1년간 무제한 애널리스트 지원

2) 제공되는 범위에 대한 모든 문의는 24~48시간 이내에 답변해 드립니다.

3) 시장 데이터가 포함된 엑셀 시트를 별도로 제공해 드립니다.

보고서 요약(영어 원문)

Market Overview
Shingles Vaccines Market is estimated to reach at a CAGR of 10.00% during the forecast period 2023 to 2030.
This vaccine is recommended in many developed countries such as the US, Canada, Germany, and the UK. In Australia, the shingles vaccines are free under the National Immunisation Program (NIP) for adults aged 70 years. Numerous economies such as Italy, the United Kingdom, and the United States have comprised this vaccination in the national immunization program of their particular countries to decrease the problem of shingles disease in their areas. Australia is providing funded facilities to give the vaccination in contradiction of shingles to individuals aged 70 to 70 years. Due to these influences, the shingles vaccines market has been projected to experience noteworthy growth paths in the coming years.
The cost-effectiveness of shingles vaccine overtreatment is a major driver for the global shingles vaccines market. The CDC-recommended vaccine, Shingrix, is a recombinant zoster vaccine with two doses administered within six months. Treatment for shingles is highly expensive and only alleviates the symptoms. Health experts widely recommend vaccination due to its effectiveness. The cost-effectiveness of shingles vaccines over treatment will be a major driver for the global shingles vaccines market during the forecast period.
What are Shingles?
Shingles, also known as herpes zoster, is a viral infection affecting the cranial nerves originating in the brain. It is caused by the varicella-zoster virus, which also causes chicken pox. The shingles vaccine is a vaccine that reduces the incidence of herpes zoster. CDC recommends that adults 50 years and older get two doses of the shingles vaccine called Shingrix (recombinant zoster vaccine) to prevent shingles and the complications from the disease. Shingle is a viral infection that is caused by the reactivation of the chickenpox virus in the body. This disease may appear as a stripe of blisters on the torso or some other part of the body and are painful even after the rash is gone. Since treatment costs for the disease only shorten the duration and lessen symptoms, vaccinations are widely recommended by the government.
Key Insights By Region:
North America is a key region for the global shingles vaccines market, mainly due to the high prevalence of shingles. The region is also home to major pharmaceutical and biotechnological companies undertaking research into new vaccines and shingle treatments. For example, in 2021, GlaxoSmithKline plc announced it had won regulatory approval for the Shingrix vaccine in U.S. and Canada. The North American shingles vaccines market is expected to undergo significant growth in the coming years.
The prevalence of shingles is relatively low in Europe; however, preventative inoculation occurs in all major European countries such as Germany, the UK, and Italy. Preventative inoculation is expected to drive the growth of the European shingles vaccines market.
The increasing prevalence of shingles in the region has opened up new opportunities for the Asia-Pacific shingles vaccines market. China reports more than 1.5 million new cases of shingles among people aged 50 and up yearly, owing to a drop in cellular immunity caused by aging. Japan also reports more than 600,000 cases of shingles each year, mainly on account of an increasingly aging population.
Market Growth Dynamics and Restraints:
The side effects associated with the shingles vaccine are expected to restrain the global shingles vaccines market:
Over the forecast period, the side effects associated with shingles vaccines are expected to prevent the growth of the global market for shingles vaccines. Most people get a sore arm with mild or moderate pain after getting the shingles vaccine and may also experience redness and swelling in the area of the shot. Other side effects include muscle pain, headache, shivering, fever, stomach pain, and nausea. Occasionally, people may get a severe allergic reaction like anaphylaxis, which can be life-threatening but is treatable.
The increasing shift towards recombinant vaccines is expected to generate new opportunities for the global market:
The recombinant shingles vaccine is recommended for adults over 50 years of age without major immune problems. It is given as a two-dose series. Although recombinant zoster vaccine requires two doses, it has an efficacy of more than 90% and offers a longer duration of protection. Therefore, the increasing shift towards recombinant vaccines is expected to create new opportunities for the market in the forecast period.
Low awareness about shingles is expected to present challenges for the global market:
As per the survey conducted by PUBMED, less than 20% of individuals surveyed in major developing countries such as India and Turkey were aware of shingles. The survey revealed almost universally poor knowledge of the causes and symptoms of shingles. The low awareness about shingles is expected to present challenges for the growth of the global shingles vaccine market.
COVID-19 Impact Analysis
The COVID-19 pandemic had a positive and a negative impact on the global market. The COVID-19 infection caused reactivation of herpes zoster in immunocompromised individuals. The pandemic also caused a decline in the production and sales of shingles vaccines as manufacturers prioritized the COVID-19 vaccine. Despite the challenges of the pandemic, the global shingles vaccines market is expected to regain growth during the forecast period.
Recent Developments in the Industry:
1. In July 2021, GlaxoSmithKline plc announced that it had won approval from the U.S. FDA for the Shingrix recombinant shingles vaccine.
2. In July 2022, Maxvax Biotechnology and Beijing Luzhu Biotechnology, two Chinese biotech companies, raised USD 74 million for multiple clinical trials of their recombinant shingles vaccines candidates.
3. In October 2021, the CDC panel voted to recommend Shingrix as a vaccine against shingles for immunodeficient or immunosuppressed adults.
Market Segmentation:
The scope of the report covers segmentation based on product, vaccine type, distribution channel, and region. The global market is segmented by product into Shingrix, Zostavax, and SKYZoster. The global shingles vaccines market is segmented by vaccine type into recombinant vaccines and live attenuated vaccines. The global shingles vaccines market is segmented by distribution channel into hospital pharmacies, retail pharmacies, and others.
1. Recombinant Vaccine: Recombinant vaccines are produced using recombinant DNA technology or genetic engineering for the prevention of lethal diseases in human beings and animals. A recombinant vaccine is a biological preparation that provides active acquired immunity against a certain disease.
2. Live Attenuated Vaccine: Live-attenuated vaccines are those in which the disease-causing pathogen remains active. Advantages of live-attenuated vaccines over some other forms of vaccines include the production of a robust, strong antibody and cell-mediated immune response, long-lasting immunity, with a relatively quick onset of action.
Competitive Analysis:
The global shingles vaccines market is consolidated and includes many major global and regional companies. The leading market players are adopting various strategies such as mergers and acquisitions, product approvals, and agreements to increase product reach and strengthen their product portfolios, to enter or expand their business offerings and competitiveness in the shingles vaccines industry.
Major Companies:
Some key companies contributing to the global shingles vaccines industry growth include GlaxoSmithKline plc., Merck & Co. Inc., SK Bioscience, GC Pharma, Vaccitech, Geneone Life Science, Shulov Innovative Science, and EYEGENE lnc., among others.
GlaxoSmithKline
Overview:
GlaxoSmithKline PLC is a global healthcare company. The Company operates through two segments: Pharmaceuticals and Vaccines. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology, and Rare diseases.
Product Portfolio:
SHINGRIX: SHINGRIX is an FDA-approved vaccine for the prevention of shingles (herpes zoster) in adults 50 years and older. SHINGRIX is not used to prevent chickenpox.
Additional Benefits Post Purchase:
1) Unlimited Analyst support for a period of 1 year.
2) Any query regarding the scope offered will be addressed within 24- 48 hours.
3) An excel sheet with market numbers will be provided separately.

상세 목차

1. Methodology and Scope
1.1. Research Methodology
1.2. Research Objective and Scope of the Report
2. Market Definition and Overview
3. Executive Summary
3.1. Market Snippet by Product
3.2. Market snippet by Vaccine Type
3.3. Market Snippet by Distribution Channel
3.4. Market Snippet by Region
4. Market Dynamics
4.1. Market Impacting Factors
4.1.1. Drivers
4.1.1.1. Inclusion of shingles vaccines in national immunization programs
4.1.1.2. Cost-effectiveness of vaccines over treatments
4.1.2. Restraints:
4.1.2.1. Low awareness regarding shingles coupled with weak product pipeline
4.1.3. Opportunity
4.1.4. Impact Analysis
5. Industry Analysis
5.1. Porter's Five Forces Analysis
5.2. Supply Chain Analysis
5.3. Pricing Analysis
5.4. Regulatory Analysis
6. COVID-19 Analysis
6.1. Analysis of Covid-19 on the Market
6.1.1. Before COVID-19 Market Scenario
6.1.2. Present COVID-19 Market Scenario
6.1.3. After COVID-19 or Future Scenario
6.2. Pricing Dynamics Amid Covid-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During Pandemic
6.5. Manufacturers Strategic Initiatives
6.6. Conclusion
7. By Product
7.1. Introduction
7.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Segment
7.1.2. Market Attractiveness Index, By Product Segment
7.2. Shingrix*
7.2.1. Introduction
7.2.2. Market Size Analysis, US$ Million, 2018-2028 and Y-o-Y Growth Analysis (%), 2020-2028
7.3. Zostavax
7.4. SKYZoster
8. By Vaccine Type
8.1. Introduction
8.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Vaccine Type
8.1.2. Market Attractiveness Index, By Vaccine Type
8.2. Recombinant Vaccine*
8.2.1. Introduction
8.2.2. Market Size Analysis, US$ Million, 2018-2028 and Y-o-Y Growth Analysis (%), 2020-2028
8.3. Live Attenuated Vaccine
9. By Distribution Channel
9.1. Introduction
9.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
9.1.2. Market Attractiveness Index, By Distribution Channel Segment
9.2. Hospital Pharmacy *
9.2.1. Introduction
9.2.2. Market Size Analysis, US$ Million, 2018-2028 and Y-o-Y Growth Analysis (%), 2020-2028
9.3. Retail Pharmacy
9.4. Others
10. By Region
10.1. Introduction
10.1.1. Market Size Analysis, US$ Million, 2018-2028 and Y-o-Y Growth Analysis (%), 2020-2028, By Region
10.1.2. Market Attractiveness Index, By Region
10.2. North America
10.2.1. Introduction
10.2.2. Key Region-Specific Dynamics
10.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product
10.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Vaccine Type
10.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
10.2.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
10.2.6.1. U.S.
10.2.6.2. Canada
10.2.6.3. Mexico
10.3. Europe
10.3.1. Introduction
10.3.2. Key Region-Specific Dynamics
10.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product
10.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Vaccine Type
10.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
10.3.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
10.3.6.1. Germany
10.3.6.2. U.K.
10.3.6.3. France
10.3.6.4. Italy
10.3.6.5. Spain
10.3.6.6. Rest of Europe
10.4. South America
10.4.1. Introduction
10.4.2. Key Region-Specific Dynamics
10.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product
10.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Vaccine Type
10.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
10.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
10.4.6.1. Brazil
10.4.6.2. Argentina
10.4.6.3. Rest of South America
10.5. Asia Pacific
10.5.1. Introduction
10.5.2. Key Region-Specific Dynamics
10.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product
10.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Vaccine Type
10.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
10.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
10.5.6.1. China
10.5.6.2. India
10.5.6.3. Japan
10.5.6.4. Australia
10.5.6.5. Rest of Asia Pacific
10.6. Middle East and Africa
10.6.1. Introduction
10.6.2. Key Region-Specific Dynamics
10.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product
10.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Vaccine Type
10.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
11. Competitive Landscape
11.1. Key Developments and Strategies
11.2. Company Share Analysis
11.3. Product Benchmarking
11.4. Key Companies to Watch
12. Company Profiles
12.1. GlaxoSmithKline plc.*
12.1.1. Company Overview
12.1.2. Product Portfolio and Description
12.1.3. Key Highlights
12.1.4. Financial Overview
12.2. Merck & Co., Inc.
12.3. SK chemicals
12.4. Green Cross Corp
12.5. Geneone Life Science
12.6. Vaccitech
12.7. CanSinoBIO (*LIST NOT EXHAUSTIVE*)
13. DataM Intelligence
13.1. Appendix
13.2. About Us and Services
13.3. Contact Us

언급된 주요 기업들

GlaxoSmithKline plc., Merck & Co., Inc., SK chemicals, Green Cross Corp, Geneone Life Science, Vaccitech

표 목록 (Tables)

List of Tables Table 01 Global Shingles Vaccines Market Value, By Product, 2021, 2025 & 2029 ($ Million)

Table 02 Global Shingles Vaccines Market Value, By Vaccine Type, 2021, 2025 & 2029 ($ Million)

Table 03 Global Shingles Vaccines Market Value, By Distribution Channel, 2021, 2025 & 2029 ($ Million)

Table 04 Global Shingles Vaccines Market Value, By Region, 2021, 2025 & 2029 ($ Million)

Table 05 Global Shingles Vaccines Market Value, By Product, 2021, 2025 & 2029 ($ Million)

Table 06 Global Shingles Vaccines Market Value, By Product, 2019-2029 ($ Million)

Table 07 Global Shingles Vaccines Market Value, By Vaccine Type, 2021, 2025 & 2029 ($ Million)

Table 08 Global Shingles Vaccines Market Value, By Vaccine Type, 2019-2029 ($ Million)

Table 09 Global Shingles Vaccines Market Value, By Distribution Channel, 2021, 2025 & 2029 ($ Million)

Table 10 Global Shingles Vaccines Market Value, By Distribution Channel, 2019-2029 ($ Million)

Table 11 Global Shingles Vaccines Market Value, By Region, 2021, 2025 & 2029 ($ Million)

Table 12 Global Shingles Vaccines Market Value, By Region, 2019-2029 ($ Million)

Table 13 North America Shingles Vaccines Market Value, By Product, 2019-2029 ($ Million)

Table 14 North America Shingles Vaccines Market Value, By Vaccine Type, 2019-2029 ($ Million)

Table 15 North America Shingles Vaccines Market Value, By Distribution Channel, 2019-2029 ($ Million)

Table 16 North America Shingles Vaccines Market Value, By Country, 2019-2029 ($ Million)

Table 17 South America Shingles Vaccines Market Value, By Product, 2019-2029 ($ Million)

Table 18 South America Shingles Vaccines Market Value, By Vaccine Type, 2019-2029 ($ Million)

Table 19 South America Shingles Vaccines Market Value, By Distribution Channel, 2019-2029 ($ Million)

Table 20 South America Shingles Vaccines Market Value, By Country, 2019-2029 ($ Million)

Table 21 Europe Shingles Vaccines Market Value, By Product, 2019-2029 ($ Million)

Table 22 Europe Shingles Vaccines Market Value, By Vaccine Type, 2019-2029 ($ Million)

Table 23 Europe Shingles Vaccines Market Value, By Distribution Channel, 2019-2029 ($ Million)

Table 24 Europe Shingles Vaccines Market Value, By Country, 2019-2029 ($ Million)

Table 25 Asia-Pacific Shingles Vaccines Market Value, By Product, 2019-2029 ($ Million)

Table 26 Asia-Pacific Shingles Vaccines Market Value, By Vaccine Type, 2019-2029 ($ Million)

Table 27 Asia-Pacific Shingles Vaccines Market Value, By Distribution Channel, 2019-2029 ($ Million)

Table 28 Asia-Pacific Shingles Vaccines Market Value, By Country, 2019-2029 ($ Million)

Table 29 Middle East & Africa Shingles Vaccines Market Value, By Product, 2019-2029 ($ Million)

Table 30 Middle East & Africa Shingles Vaccines Market Value, By Vaccine Type, 2019-2029 ($ Million)

Table 31 Middle East & Africa Shingles Vaccines Market Value, By Distribution Channel, 2019-2029 ($ Million)

Table 32 GlaxoSmithKline plc.: Overview

Table 33 GlaxoSmithKline plc.: Product Portfolio

Table 34 GlaxoSmithKline plc.: Key Developments

Table 35 Merck & Co.: Overview

Table 36 Merck & Co.: Product Portfolio

Table 37 Merck & Co.: Key Developments

Table 38 SK chemicals: Overview

Table 39 SK chemicals: Product Portfolio

Table 40 SK chemicals: Key Developments

Table 41 Green Cross Corp: Overview

Table 42 Green Cross Corp: Product Portfolio

Table 43 Green Cross Corp: Key Developments

Table 44 Geneone Life Science: Overview

Table 45 Geneone Life Science: Product Portfolio

Table 46 Geneone Life Science: Key Developments

Table 47 Vaccitech: Overview

Table 48 Vaccitech: Product Portfolio

Table 49 Vaccitech: Key Developments

Table 50 CanSinoBIO: Overview

Table 51 CanSinoBIO: Product Portfolio

Table 52 CanSinoBIO: Key Developments

그림 목록 (Figures)

List of Figures Figure 01 Global Shingles Vaccines Market Share, By Product, 2021 & 2029 (%)

Figure 02 Global Shingles Vaccines Market Share, By Vaccine Type, 2021 & 2029 (%)

Figure 03 Global Shingles Vaccines Market Share, By Distribution Channel, 2021 & 2029 (%)

Figure 04 Global Shingles Vaccines Market Share, By Region, 2021 & 2029 (%)

Figure 05 Global Shingles Vaccines Market Value, 2019-2029 ($ Million)

Figure 06 Global Shingles Vaccines Market Y-o-Y Growth, By Product, 2021-2029 (%)

Figure 07 Shingrix: Global Shingles Vaccines Market Value, 2019-2029 ($ Million)

Figure 08 Zostavax: Global Shingles Vaccines Market Value, 2019-2029 ($ Million)

Figure 09 SKYZoster: Global Shingles Vaccines Market Value, 2019-2029 ($ Million)

Figure 10 Global Shingles Vaccines Market Y-o-Y Growth, By Vaccine Type, 2021-2029 (%)

Figure 11 Recombinant Vaccine: Global Shingles Vaccines Market Value, 2019-2029 ($ Million)

Figure 12 Live Attenuated Vaccine: Global Shingles Vaccines Market Value, 2019-2029 ($ Million)

Figure 13 Global Shingles Vaccines Market Y-o-Y Growth, By Distribution Channel, 2021-2029 (%)

Figure 14 Hospital Pharmacy: Global Shingles Vaccines Market Value, 2019-2029 ($ Million)

Figure 15 Retail Pharmacy: Global Shingles Vaccines Market Value, 2019-2029 ($ Million)

Figure 16 Others: Global Shingles Vaccines Market Value, 2019-2029 ($ Million)

Figure 17 Global Shingles Vaccines Market Y-o-Y Growth, By Region, 2021-2029 (%)

Figure 18 North America Shingles Vaccines Market Value, 2019-2029 ($ Million)

Figure 19 North America Shingles Vaccines Market Share, By Product, 2021 & 2029 (%)

Figure 20 North America Shingles Vaccines Market Share, By Vaccine Type, 2021 & 2029 (%)

Figure 21 North America Shingles Vaccines Market Share, By Distribution Channel, 2021 & 2029 (%)

Figure 22 North America Shingles Vaccines Market Share, By Country, 2021 & 2029 (%)

Figure 23 South America Shingles Vaccines Market Value, 2019-2029 ($ Million)

Figure 24 South America Shingles Vaccines Market Share, By Product, 2021 & 2029 (%)

Figure 25 South America Shingles Vaccines Market Share, By Vaccine Type, 2021 & 2029 (%)

Figure 26 South America Shingles Vaccines Market Share, By Distribution Channel, 2021 & 2029 (%)

Figure 27 South America Shingles Vaccines Market Share, By Country, 2021 & 2029 (%)

Figure 28 Europe Shingles Vaccines Market Value, 2019-2029 ($ Million)

Figure 29 Europe Shingles Vaccines Market Share, By Product, 2021 & 2029 (%)

Figure 30 Europe Shingles Vaccines Market Share, By Vaccine Type, 2021 & 2029 (%)

Figure 31 Europe Shingles Vaccines Market Share, By Distribution Channel, 2021 & 2029 (%)

Figure 32 Europe Shingles Vaccines Market Share, By Country, 2021 & 2029 (%)

Figure 33 Asia-Pacific Shingles Vaccines Market Value, 2019-2029 ($ Million)

Figure 34 Asia-Pacific Shingles Vaccines Market Share, By Product, 2021 & 2029 (%)

Figure 35 Asia-Pacific Shingles Vaccines Market Share, By Vaccine Type, 2021 & 2029 (%)

Figure 36 Asia-Pacific Shingles Vaccines Market Share, By Distribution Channel, 2021 & 2029 (%)

Figure 37 Asia-Pacific Shingles Vaccines Market Share, By Country, 2021 & 2029 (%)

Figure 38 Middle East & Africa Shingles Vaccines Market Value, 2019-2029 ($ Million)

Figure 39 Middle East & Africa Shingles Vaccines Market Share, By Product, 2021 & 2029 (%)

Figure 40 Middle East & Africa Shingles Vaccines Market Share, By Vaccine Type, 2021 & 2029 (%)

Figure 41 Middle East & Africa Shingles Vaccines Market Share, By Distribution Channel, 2021 & 2029 (%)

Figure 42 GlaxoSmithKline plc.: Financials

Figure 43 Merck & Co.: Financials

Figure 44 SK chemicals: Financials

Figure 45 Green Cross Corp: Financials

Figure 46 Geneone Life Science: Financials

Figure 47 Vaccitech: Financials

Figure 48 CanSinoBIO: Financials